Hydrogel Endovascular Aneurysm Treatment Trial (HEAT)

• ClinicalTrials.gov Identifier: NCT01407952
• Recruitment Status: Completed
• First Posted: August 2, 2011
• Results First Posted: June 27, 2019
• Last Update Posted: June 27, 2019
• Sponsor: Northwestern University
• Collaborator: MicroVention, Inc.
• Information provided by (Responsible Party): Bernard Bendok, Northwestern University

Tracking Information

• First Submitted Date: July 12, 2011
• First Posted Date: August 2, 2011
• Results First Submitted Date: March 31, 2019
• Results First Posted Date: June 27, 2019
• Last Update Posted Date: June 27, 2019
• Study Start Date: April 2012
• Actual Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: June 10, 2019)

Number of Patients With Aneurysm Recurrence Post Surgery [ Time Frame: post surgery to 24 months ]

Defined as any progression on the Raymond-Roy (RR) Aneurysm Occlusion Scale. The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.

• Original Primary Outcome Measures (submitted: August 1, 2011): Aneurysm recurrence at any point during follow-up. [ Time Frame: 18 months ]

Current Secondary Outcome Measures (submitted: June 10, 2019)

• Packing Density [ Time Frame: at operation ]
  Packing density as measured by volumetric filling of the aneurysm
• Clinical Outcome: Modified Rankin Scale (mRS) [ Time Frame: 24 months ]
  modified rankin scale is a measure of neurological disability, which ranges from 0=no symptoms to 5=severe disability (6=dead).
• Number of Participants With Adverse Events Related to the Procedure and/or the Device by Participant at Any Time in the Study. [ Time Frame: 24 months ]
  number of participants who experienced any peri-procedural or post-procedural Adverse Event noted to be related to the procedure or device.
• Total Number of Peri-procedural and Post-procedural Adverse Events Related to the Procedure and/or the Device. [ Time Frame: 24 months ]
  total number of Adverse Events per person that were noted to be related to the procedure and device during the study
• Number of Patients Who Expired During the Study (Mortality Rate) [ Time Frame: 24 months ]
  all-cause mortality at any time during study follow-up
• Number of Participants With Initial Complete Occlusion [ Time Frame: at procedure ]
  Raymond-Roy (RR) Scale=1 at procedure The RR scale is such that 1=complete occlusion, 2=residual neck, and 3=residual aneurysm.
• Number of Patients Who Needed Re-treatment of Target Aneurysm [ Time Frame: 24 months ]
  During the 24 month follow-up, if Aneurysm needed to be re-treated.
• Number of Participants Experiencing a Hemorrhage From Target Aneurysm Post Surgery [ Time Frame: 24 months ]
  Per the Adverse event log, if a hemorrhage or rupture occurred that was noted to be related to the procedure or device at any point during the 24 month follow-up (not during the operation).
• Number of Participants Who Progressed on the Meyers Scale [ Time Frame: 24 months ]
  Occlusion (in)stability was determined by progression on the Meyers scale. The Meyer scale is a 6-point grading scale based on the percentage of the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents greater than 90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, less than 25% volumetric aneurysm occlusion.
• Number of Participants Experiencing Major Versus Minor Recurrence by 24 Months Follow-up. [ Time Frame: 24 months ]
  Major recurrence is defined as progression on the Raymond-Roy (RR) Scale to 3, or if initial RR was 3, then progression on the Meyers scale. Minor recurrence was defined as a progression on the RR scale to 2. The RR scale is a 3 point measure of occlusion, 1=total, 2=residual neck, and 3=residual aneurysm. The Meyer scale is a 6-point grading scale based on the percentageof the aneurysm filled by contrast on DSA. Grade zero indicates complete and total aneurysm occlusion without remnant or in-terstitial filling within the aneurysm. Grade 1 represents >90%volumetric occlusion of the aneurysm based on planar imaging assessment; grade 2, 70%-89% aneurysm occlusion; grade 3,50%-69%; grade 4, 25%-49%; and grade 5, <25% volumetric aneurysm occlusion.

Original Secondary Outcome Measures (submitted: August 1, 2011)

Clinical outcome [ Time Frame: 18 months ]

Packing density as measured by volumetric filling of the aneurysm Clinical outcome at 18 months (mRS) Peri-procedural and post-procedural adverse events related to the procedure and/or the device. Mortality rate Initial Complete occlusion Aneurysm retreatment Aneurysm re-hemorrhage

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Hydrogel Endovascular Aneurysm Treatment Trial
• Official Title: New Generation Hydrogel Endovascular Aneurysm Treatment Trial

Brief Summary

This research study is being done to test the effectiveness of a new generation FDA approved device for treating aneurysms compared to the current standard device for endovascular aneurysm treatment which is bare platinum coils. Endovascular procedures are a form of minimally invasive surgery, which is performed on blood vessels. The technique involves the introduction of a catheter which is a long, thin, flexible, hollow plastic tube through the skin into a large blood vessel. Typically the chosen blood vessel is the femoral artery found near the groin. The catheter is then maneuvered through the body to the location of the aneurysm in the brain using image guidance. Coils are delivered into the aneurysm through the catheters. Once the coils are delivered in the aneurysm, they are detached from the catheter. This is repeated until enough coils fill the aneurysm, blocking the blood flow to the aneurysm. The body responds by forming blood clots around the coil(s), which helps block the flow of blood into the aneurysm and keeps the vessel from rupturing or leaking. This study will compare the study device to the standard bare platinum coil to see which is better at preventing future rupturing or leaking. The study device is called the HydroCoil Embolization System and this study is a post-market clinical trial.

About 600 subjects from multiple institutions will take part in this study.

Detailed Description

Your part in this study will last up to 24 months and will involve 6 visits (1 baseline visit before your surgery, the surgical procedure and 4 follow-up visits). These visits will occur at the same time as the visits you would receive as standard of care after your surgery.

If you are in this study, you will be placed in one of two study groups by chance using a process similar to the flip of a coin. This process is called randomization. Neither you nor the study staff will select the group you will be in. One group, the control group, will have their aneurysm treated by the bare platinum coils during their endovascular procedure. The other group, the study group will receive coils from the HydroCoil Embolization System. Both groups will receive the same standard of care and follow-up, but during the surgery different types of coils will be used.

• Study Type: Interventional
• Study Phase: Not Applicable
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Cerebral Aneurysm

Intervention

• Device: HydroCoil Embolic System
  HydroCoil Embolic System
  Other Name: MicroVention, Inc
• Device: Control (bare platinum coils)
  bare platinum coils

Study Arms

• HydroCoil Embolic System
  Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
  Intervention: Device: HydroCoil Embolic System
• Control
  Aneurysm treatment using bare platinum coil(s)
  Intervention: Device: Control (bare platinum coils)

• Publications *: Bendok BR, Abi-Aad KR, Ward JD, Kniss JF, Kwasny MJ, Rahme RJ, Aoun SG, El Ahmadieh TY, El Tecle NE, Zammar SG, Aoun RJN, Patra DP, Ansari SA, Raymond J, Woo HH, Fiorella D, Dabus G, Milot G, Delgado Almandoz JE, Scott JA, DeNardo AJ, Dashti SR; HEAT Study Investigators. The Hydrogel Endovascular Aneurysm Treatment Trial (HEAT): A Randomized Controlled Trial of the Second-Generation Hydrogel Coil. Neurosurgery. 2020 May 1;86(5):615-624. doi: 10.1093/neuros/nyaa006.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: August 1, 2011): 600
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: March 2018
• Actual Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

Candidates for this study must meet the following criteria to be enrolled in the study:

1. Patient is between 18 and 75 years of age (inclusive).
2. Patient has a documented untreated intracranial saccular aneurysm 3-14 mm diameter angiographic lumen, ruptured or unruptured, suitable for embolization with coils.
3. Patients presenting with a HUNT and HESS Grade 0-3 or improving to such a grade before treatment
4. Any type of bare platinum coils and HydroCoil ® Coils are treatment options (all shapes allowed).
5. Patient or next of kin or person with appropriate power of attorney has provided written informed consent.
6. Patient is willing and available for study follow-up visits
7. Patient has not been previously entered into this Study

Exclusion Criteria:

Candidates will be ineligible for enrollment in the study if any of the following conditions apply:

1. Inability to obtain informed consent
2. Patient is < 18 or > 75 years old
3. Target aneurysm is not saccular in nature (mycotic, fusiform, dissecting).
4. Target aneurysm is > 14 mm maximum luminal dimension, < 3 mm maximum luminal dimension
5. Target aneurysm has been previously clipped or coiled
6. Target aneurysm is in the physician's estimate unlikely to be successfully treated by endovascular techniques.
7. Patient has known hypersensitivity to platinum, nickel, stainless steel or structurally related compounds found in HydroCoil®, HydroSoft®, HydroFrame® Coils and/or bare platinum coils.
8. Baseline Hunt and Hess scale 4 or 5 for ruptured aneurysms
9. Intended use of a flow diverting stent (e.g. pipeline)

10. Subject has concurrent intracranial pathology, e.g.

    • Moyamoya
    • Vasculitis documented by biopsy results
    • AVMs
    • AV fistulas
    • Significant atherosclerotic disease (i.e. symptomatic and or >50% narrowing of the parent arteries necessary to traverse in order to coil the target aneurysm)
    • Intracranial Hematoma (unrelated to the target aneurysm)
    • Brain tumors
    • Vascular tortuosity and other conditions preventing access to target aneurysm

11. Subject has serious co-morbidities that could confound the study results:

    • Uncontrolled hypertension
    • Uncorrectable coagulation abnormality
    • Contraindications for heparin, aspirin or clopidogrel
    • Uncontrolled Diabetes Mellitus
    • Organ failure of kidney, liver, heart, or lung
    • Myocardial infarction within the past 6 months
    • Cancer likely to cause death within 2 years or less.
12. Subject history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.)
13. Subject has a known history contraindicating contrast dye or iodine that cannot be pre-medicated prior to coiling procedure (vs. sensitivity which can be safely controlled by antihistamine, steroid, etc.). Medical clearance will be needed for this issue.
14. Patients who are unable to complete scheduled follow up assessments at the enrolling center due to limited life expectancy (<2 years), co-morbidities or geographical considerations
15. Subject is currently breast feeding, pregnant or plans to become pregnant in the next 2 years.
16. Major surgical procedure or trauma within 30 days prior to randomization
17. The patient is currently enrolled in another clinical study (device or drug).
18. More than one aneurysm needing treatment at the same time.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 75 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, United States

Administrative Information

• NCT Number: NCT01407952
• Other Study ID Numbers: HEAT_protocol1
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Bernard Bendok, Northwestern University
• Original Responsible Party: Bernard Bendok, MD/Associate Professor, Northwestern University
• Current Study Sponsor: Northwestern University
• Original Study Sponsor: Same as current
• Collaborators: MicroVention, Inc.

Investigators

• Principal Investigator: Bernard R Bendok, MD; Mayo Clinic

• PRS Account: Northwestern University
• Verification Date: June 2019